Patents Examined by Emily Bernhardt
  • Small-molecule HSP90 inhibitors
    Patent number: 10676476
    Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: June 9, 2020
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gabriela Chiosis, Huazhong He, Laura Llauger-Bufi, Joungnam Kim, Steven M. Larson, Peter Smith-Jones
  • Crystalline forms of an NK-1 antagonist
    Patent number: 10676440
    Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: June 9, 2020
    Assignee: Helsinn Healthcare SA
    Inventors: Christian Bacilieri, Gionata Frasca
  • Compound for the prophylaxis or treatment of organ damage
    Patent number: 10676452
    Abstract: The present invention relates to compounds for prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially to compounds for prophylaxis or treatment of diabetic kidney damage. Specifically, the present invention relates to 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)(piperazin-1-yl)methanone or N,6-dihydroxy-2,5,7,8-tetramethylchroman-2-carboxamide or a pharmaceutically acceptable salt or base thereof for use in the prophylaxis or treatment of organ damage by restoring endothelial function and/or inhibiting reactive oxygen species production and especially diabetic kidney organ damage.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: June 9, 2020
    Assignee: Sulfateq B.V.
    Inventors: Adrianus Cornelis Van Der Graaf, Robert Henk Henning, Leo Edwin Deelman, Gerrit Jan Willem Euverink
  • Pesticidal compositions
    Patent number: 10674728
    Abstract: The present invention relates to pesticidal compositions. In particular it relates to composition comprising a compound of formula (I) and a further active ingredient. Such compositions are useful for the control of pests and/or for improving the yield of crop plants.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 9, 2020
    Assignee: Syngenta Participations AG
    Inventors: Philippe Camblin, Arne Pingel
  • Tetrahydronaphthyl urea derivative
    Patent number: 10669239
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 2, 2020
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Hiroshi Nagasue
  • 3-sulfonyl-5-aminopyridine-2,4-diol APJ agonists
    Patent number: 10669258
    Abstract: The present invention provides compounds of Formula (I) wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: June 2, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jeremy M. Richter, J. Alex Bates
  • Process for the preparation of macitentan
    Patent number: 10669264
    Abstract: The present invention relates to an improved process for the preparation of macitentan and pharmaceutical acceptable salts thereof. Further present invention also relates to methylene chloride solvate of macitentan and their use in the preparation of pure macitentan.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 2, 2020
    Assignee: Laurus Labs Limited
    Inventors: Srivardhana Rao Jamjanam, Venkata Ramakrishna Murthy Moturu, Venkata Sunil Kumar Indukuri, Srihari Raju Kalidindi, Satyanarayana Chava
  • BTK inhibitor
    Patent number: 10662174
    Abstract: Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 26, 2020
    Assignee: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC.
    Inventors: Xuehai Wang, Chengde Wu, Yong Xu, Chunli Shen, Li'e Li, Guoping Hu, Yang Yue, Jian Li, Diliang Guo, Nengyang Shi, Lu Huang, Shuhui Chen, Ronghua Tu, Zhongwen Yang, Xuwen Zhang, Qiang Xiao, Hua Tian, Yanping Yu, Hailiang Chen, Wenjie Sun, Zhenyu He, Jie Shen, Jing Yang, Jing Tang, Wen Zhou, Jing Yu, Yi Zhang, Quan Liu
  • Process for preparing a compound useful to treat mycoses
    Patent number: 10662179
    Abstract: A process for preparing a compound of formula (I): includes reacting a compound of formula (II): with a compound of formula (III):
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: May 26, 2020
    Assignee: PULMOCIDE LIMITED
    Inventors: Thomas Christopher Colley, Kazuhiro Ito, Garth Rapeport, Peter Strong, Peter John Murray, Stuart Thomas Onions, Mihiro Sunose
  • Small molecule NF-?B inhibitors
    Patent number: 10660894
    Abstract: The present invention provides, inter alia, compounds capable of inhibiting NF-?B. Pharmaceutical compositions containing and methods of using the compounds are also provided herein.
    Type: Grant
    Filed: January 10, 2019
    Date of Patent: May 26, 2020
    Assignee: ImmuneTarget, Inc.
    Inventors: Samedy Ouk, Hsiou-Chi Liou
  • Substituted quinazoline and pyridopyrimidine derivatives useful as anticancer agents
    Patent number: 10662204
    Abstract: Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and administration of these compounds to patients to treat pancreatic, lung, colon and other cancers.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: May 26, 2020
    Assignee: Pfizer Inc.
    Inventors: Simon Planken, Hengmiao Cheng, Michael Raymond Collins, Jillian Elyse Spangler, Alexei Brooun, Andreas Maderna, Cynthia Palmer, Maria Angelica Linton, Asako Nagata, Ping Chen
  • Pyrimidoquinazoline pigment, method for manufacturing pyrimidoquinazoline pigment, and pigment colorant
    Patent number: 10655017
    Abstract: The present invention provides a pyrimidoquinazoline pigment having a novel pyrimidine skeleton, the pyrimidoquinazoline pigment having excellent pigment properties, such as coloring power and durability, and excellent infrared reflectivity and a method for producing the pyrimidoquinazoline pigment, and a pigment colorant using the pyrimidoquinazoline pigment. The present invention relates to a pyrimidoquinazoline pigment represented by the following formula (1), wherein R1 and R2 each independently represent a benzene ring or a naphthalene ring optionally having a substituent, and a method for producing the pyrimidoquinazoline pigment. In addition, the present invention relates to a pigment colorant containing the pyrimidoquinazoline pigment.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 19, 2020
    Assignee: DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD.
    Inventors: Kazuki Iguchi, Naomi Oguma, Atsushi Nogami, Shuwa Ozako
  • Pyridazinones and methods of use thereof
    Patent number: 10654850
    Abstract: Disclosed are compounds according to Formula (I), and related pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I).
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: May 19, 2020
    Assignee: Goldfinch Bio, Inc.
    Inventors: Mark W. Ledeboer, Matthew H. Daniels, Maolin Yu, Jean-Christophe P. Harmange
  • Metabotrophic glutamate receptor 5 modulators and methods use thereof
    Patent number: 10640510
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 5, 2020
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Imidazopyrazinamine phenyl derivative and use thereof
    Patent number: 10640512
    Abstract: Imidazopyrazinamine phenyl derivatives, pharmaceutically acceptable salts and hydrates thereof, or metabolites thereof formed by any form of metabolism, and uses thereof in the preparation of medicaments for preventing and/or treating indications/diseases associated with BTK functions are disclosed. The disclosed imidazopyrazinamine phenyl derivatives are ideal high-efficient BTK inhibitors for treating or preventing diseases such as rheumatoid arthritis, B cell lymphoma, leukemia, multiple myeloma, allergies, asthma, multiple sclerosis, type I diabetes and systemic lupus erythematosus.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 5, 2020
    Assignee: HANGZHOU SANYINTAI PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Jianming Yin, Yubin Lv, Bangliang Li
  • Diphenyl derivatives and uses thereof
    Patent number: 10633350
    Abstract: The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: April 28, 2020
    Assignee: NOVARTIS AG
    Inventors: Natalie Dales, Paul Gormisky, John Ryan Kerrigan, Lei Shu
  • Phenyl indole allosteric inhibitors of p97 ATPase
    Patent number: 10633370
    Abstract: The present invention is directed to methods of inhibiting p97 and compounds and compositions useful in such methods. Diseases and conditions the can be treated with the compounds and compositions of the invention include, but are not limited to, cancer and neurodegenerative disorders susceptible to treatment by inhibition of p97.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 28, 2020
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, National Institutes of Health, A Component of the U.S. Department of Health and Human Services, The Regents of the University of California
    Inventors: Donna M. Huryn, Peter Wipf, Matthew G. LaPorte, Raffaele Colombo, Marina Kovaliov, Chaemin Lim, Celeste Natalie Alverez, Zhizhou Yue, Lalith Palitha Samankumara, Alexander Julian Chatterley, Yongzhao Yan, Mary Liang, Neal J. Green, Eric T. Baldwin, William J. Moore, Michelle Arkin, R. Jeffrey Neitz, Kean-Hooi Ang, Clifford Bryant, Stacie Bulfer
  • Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
    Patent number: 10626107
    Abstract: A crystal form and a salt type of a substituted 2-hydro-pyrazole derivative, preparation method therefor, and use of the crystal form and the salt type in preparation of a medicament for treating cancers such as breast cancer, lung cancer and the like.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: April 21, 2020
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Charles Z. Ding, Shuhui Chen, Lihong Hu, Zhaobing Xu, Yingchun Liu, Bingjie Ren, Weidong Li, Zongbin Li, Rui Zhao, Xiquan Zhang
  • Agent against fungal infections
    Patent number: 10624892
    Abstract: The invention relates to fungicides and can be used for treating diseases caused by fungi, and also for preventing fungal damage to various materials and agricultural products. Claimed is an agent against fungal infections which is in the form of salts of 2,4-dioxo-5-arylideneamino-6-methyl-1,3-pyrimidine, where R is 4-NO2, 2-OH-5-NO2, 2-OH-3,5-Cl2, 5-Br-4-OH-3-OCH3, 2-OH-5-Cl, 2,4-Cl2, 3,5-Br2-2-OH. The result is an agent against fungal infections which has a broad spectrum of activity and is highly soluble, rendering it more effective for use in the form of solutions.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: April 21, 2020
    Assignees: Viktor Veniaminovich TETS, Georgy Viktorovich TETS
    Inventors: Viktor Veniaminovich Tets, Georgy Viktorovich Tets
  • Organic electroluminescent compound and organic electroluminescent device comprising the same
    Patent number: 10629824
    Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure has a high glass transition temperature that can be used in a deposition process. In addition, an organic electroluminescent device having low driving voltage, a high luminous efficiency and/or long lifespan characteristic can be provided with the use of the organic electroluminescent compound according to the present disclosure.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: April 21, 2020
    Assignee: Rohm and Haas Electronic Materials Korea Ltd
    Inventors: Doo-Hyeon Moon, Yeon-Gun Lee